What is Turbine?
Turbine operates at the intersection of artificial intelligence and pharmacology, developing a sophisticated virtual lab platform that simulates complex biological experiments. The company's core value proposition lies in its ability to help life science teams prioritize therapeutic targets, design optimal drug combinations, and generate decision-ready hypotheses for clinical validation. By replacing traditional, time-intensive wet-lab processes with predictive computational models, Turbine significantly reduces the risk and cost associated with early-stage drug development. This market position is increasingly vital as pharmaceutical companies seek to accelerate their R&D cycles and improve the success rates of novel therapeutics in a highly competitive global landscape.
How much funding has Turbine raised?
Turbine has raised a total of $61.7M across 4 funding rounds:
Other Financing Round
$3.4M
Other Financing Round
$6.8M
Series A
$26.5M
Series B
$25M
Other Financing Round (2019): $3.4M with participation from Atlantic Labs, Delin Ventures, o2h Ventures, Esther Dyson, and Vishal Gulati
Other Financing Round (2021): $6.9M led by Boston Millenia Partners, Atlantic Labs, Accel, Delin Ventures, XTX Ventures, and o2h Ventures
Series A (2023): $26.5M supported by Day One Capital, Accel, Delin Ventures, Mercia Asset Management, and MassMutual Ventures
Series B (2026): $25M featuring Mercia Technologies, Accel, Interactive Venture Partners, and Beiersdorf
Key Investors in Turbine
Accel
Accel is a global venture capital firm that partners with exceptional teams from the inception of their ideas through all phases of private company growth, focusing on supporting innovative companies and entrepreneurs.
Mercia Asset Management
Mercia Asset Management provides equity and debt financing to UK businesses with growth ambitions, acting as investment partners from scale-up to exit to accelerate growth and impact.
Interactive Venture Partners
Interactive Venture Partners is an investment firm focused on providing capital to ambitious entrepreneurs and startups in Hungary and Central Eastern Europe, backed by Thomas Peterffy.
What's next for Turbine?
With the successful closure of its latest financing round, Turbine is well-positioned to scale its operations and expand the capabilities of its simulation engine. The company's strategic roadmap likely involves deepening its integration with existing pharmaceutical workflows and potentially expanding its reach into new therapeutic areas. As the industry shifts toward data-driven drug discovery, Turbine's ability to provide actionable insights will be a key differentiator. The continued support from institutional investors suggests a strong confidence in the company's long-term potential to redefine the economics of drug development and deliver transformative outcomes for patients worldwide.
See full Turbine company page
